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Objective: Stent grafts are increasingly recognized as useful devices for endovascular repair of aortic aneurysms and other
vascular diseases. Stent graft-mediated gene delivery into the vascular wall is expected to improve their therapeutic effects.
This study evaluated the efficacy of genetically engineered cationized gelatin (CG) hydrogel-coated partially-covered
polyester stent grafts that facilitate delivery of an expression plasmid DNA in rabbit aortic wall.
Methods: Partially covered polyester stent grafts coated with CG hydrogel impregnated with 10.0 mg/mL of -galactosidase
(LacZ)-expression plasmid vector (pCAGGS-LacZ) or empty vector (pCAGGS) solutions were implanted via the femoral artery in
rabbit balloon-injured aortas. The aortic segments were removed at 1, 3, or 7 days (4 rabbits/each group) after implantation and
evaluated for the transgene (LacZ) delivery and expression by real-time reverse transcriptase polymerase chain reaction (RT-PCR)
andX-gal (5-bromo-4-chloro-3-indolyl--D-galactoside) staining.Partially-coveredpolyester stent grafts coatedwithCGhydrogel
impregnated with various amounts (0.1 mg/mL, 1.0 mg/mL, and 10.0 mg/mL) of pCAGGS-LacZ or pCAGGS were also
implanted in rabbits’ balloon-injured aortas (4 rabbits/each group) to evaluate transgene delivery and expression in the aortic wall
3days after implantation.Thedifference of transgene efficiency among eachgroupwas comparedusingone-way analysis of variance
(ANOVA) and Newman-Keuls’ test according to the result of quantitative RT-PCR.
Results: In all animals, LacZ gene transduction into the aortic wall was detected at the implantation site of pCAGGS-LacZ-
loaded, but not pCAGGS-loaded, stent grafts. LacZ expression was not detected in aortic segments immediately proximal or
distal to the implanted pCAGGS-LacZ-loaded stent graft or remote organs including the brain, heart, liver, and kidney by
either RT-PCR or X-gal staining. The X-gal staining-positive cells were observed at or near the luminal surface in the aortic
segments only in contact with the stent graft and the ingrowth tissues within stent grafts. Immunohistochemical studies
suggested that the LacZ-positive cells were mainly the neointimal -smooth-muscle actin-positive cells and macrophages. The
extent of the transgene expression was dependent on the quantity of the plasmid DNA loaded onto the stent graft (10.0
mg/mL plasmid vs 1.0 mg/mL plasmid, P< .01 and 10.0 mg/mL plasmid vs 0.1 mg/mL plasmid, P< .05). LacZ mRNA
expression was maximal at day 1 and declined at day 7 (P < .05) but was still detectable.
Conclusion:Plasmid-loadedCGhydrogel-coated stent graft is a promising vehicle for local transgene delivery to the aortic wall
and offers the possibility of transduction of therapeutic genes into the vascular wall. (J Vasc Surg 2009;50:1433-43.)
Clinical Relevance: Plasmid-loaded cationized gelatin (CG) hydrogel-coated stent graft offers the possibility of trans-
duction of therapeutic genes into the vascular wall. It may become relevant in interventional radiology in the future for
inducing the regression of aortic aneurysm or treatment of atherosclerosis and improving graft function by facilitating the
biologic healing between the aorta and graft.Abdominal aortic aneurysm (AAA) is recognized as a
life-threatening vascular disease. Endovascular aortic aneu-
rysm repair (EVAR) has been accepted as an alternative to
conventional open surgery in anatomically-suitable patients,
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doi:10.1016/j.jvs.2009.07.071because it is less invasive and results in less blood loss and
lower rates of mortality/morbidity.1-3 However, the
endoleaks, graft migration4-6 or late kinks,7 progression
of aneurysm along the aneurysm neck, and expansion of
aneurysmal neck8,9 can cause aneurysm rupture or graft
occlusion. One of the contributing factors of these com-
plications may be that endovascular grafts do not incor-
porate well enough with an aortic wall, especially in the
case of an irregular aortic inner surface due to arterio-
sclerosis with variously sized spaces remaining between
the graft and aortic wall.10
Delivery of a desired therapeutic gene into the vas-
cular wall would be expected to facilitate fixation of the
stent grafts in aortas and to ameliorate atherosclerosis of
the aortic wall or to prevent aneurysm progression. Gene
delivery to the localized arterial wall commonly involves
catheter-based infusions of DNA solutions11,12 or local
gene transfer by gene-eluting stents.13-15 However, the
former is not possible because of various potential risks
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coronary arteries and may not be suitable for diffuse gene
delivery to the aortic wall. As for the vector for intravas-
cular gene delivery, both viral and nonviral vectors have
been employed experimentally, and now nonviral vec-
tors, such as plasmid DNA, are considered to be better
despite their much lower gene transfer efficiency than
viral vectors because of their safety and ease of use.16,17
Therefore, ways to improve the efficiency of plasmid
DNA transfection are now being actively sought.
We previously demonstrated the efficacy of CG hydro-
gel for controlled release of plasmid DNA.18,19 Plasmid
DNA was released associated with the in vivo degradation
of hydrogel, resulting in extended gene expression, and the
time profile of plasmid DNA release and the consequent
gene expression were controllable by changing the extent
of cross-linking of the hydrogels.
The purpose of this study was to evaluate the efficacy
of genetically engineered CG hydrogel-coated partially-
covered polyester stent grafts that facilitate delivery of an
expression plasmid DNA in rabbit aortic wall and to
explore the feasibility of gene expression in the aortic
tissue.
MATERIALS AND METHODS
Preparation of cationized gelatin hydrogel-coated
handmade partially-covered polyester stent grafts.
Handmade partially-covered polyester stent graft 10 mm in
length and 7 mm in diameter (Fig 1, a) was made as
Fig 1. a, Partially-covered polyester stent graft; b, X-ra
CG hydrogel-coated partially-covered stent grafts (blackpreviously described.20 Polyester fabric with a porosity of2268 mL/min/cm2 was sutured on a one-body stainless
steel Z-stent with 12 struts. To decrease the stent profile
and facilitate its delivery into rabbit aorta via the femoral
approach through a 6F catheter introducer, one third of the
fabric was cut down. The CG with a consistency of 10%
wt/wt at 40°C was prepared by processing pig skin type I
collagen (molecular weight 99000; Nitta Gelatine Co,
Osaka, Japan) as described previously.18,19 The degrada-
tion of this gelatin preparation would last for around 7 days
with the degradation half-life of 1 day.19 The partially-
covered polyester stent grafts were rendered hydrophilic
and dip-coated with CG followed by cross-linking de-
scribed previously.18,19 At last, the CG hydrogel-coated
stent grafts were freeze-dried and sterilized with ethylene
oxide gas for preservation.18 The average coating weight in
the multiple preparations, which was determined by mea-
suring the weight of stent grafts before and after CG
hydrogel-coating and freeze-drying in 10 stent grafts, was
3.0  1.1 mg per stent graft. Complete coating was con-
firmed by scanning electron microscopy (data not shown).
Incorporation of plasmid DNA into cationized
gelatin hydrogel-coated stent grafts. The mammalian
expression plasmid vector pCAGGS encoding bacterial
-galactosidase (LacZ) cDNA (pCAGGS-LacZ, 7903 base
pairs [bps]), in which LacZ mRNA transcription is driven
by the actin-globin (AG) hybrid promoter with cytomega-
lovirus (CMV)-IE enhancer inserted upstream of LacZ
gene, was employed. The CG hydrogel-coated stent grafts
were loaded with the plasmidDNA by dipping dried coated
of the rabbit that underwent the implantation of three
s) in the aorta via right femoral artery.y filmstent grafts in TE (10mMTris and 1mMEDTA [pH 8.0])
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LacZ for 12 hours at 4°C. Plasmid-loaded CG hydrogel-
coated stent grafts were implanted into the aorta of rabbits
within 10 minutes. The amount of plasmid DNA absorbed
by CG hydrogel on stent grafts was assessed by using
125I-labelled pCAGGS-LacZ as described previously.10,18
The percentage of plasmid DNA absorbed by CG hydrogel
on the stent graft was 81.9% 2.2%. Absorption of plasmid
DNA onto non-CG hydrogel-coated stent grafts was min-
imal. After the stent grafts were mounted in and pushed
through the 6F sheath of the delivery system in vitro, the
residual amount of pCAGGS-LacZ after simulating stent
graft delivery was 94.3%  2.4%.
Animals and study design. All animals (24 male Jap-
anese white rabbits [3.93  0.16 kg]) received humane
care, and all procedures were approved by the Animal Care
Committee in accordance with the guidelines of our uni-
versity. Because the preliminary study revealed that the
transduction efficiency was very low in the normal aortic
wall, and the atherosclerotic aorta in which the neointima
exists21 was supposed to be subjected to the future appli-
cation of this technique in clinical practice, all rabbits
underwent balloon injury22,23 in the descending thoracic
aorta and the proximal abdominal aorta 4 weeks before CG
hydrogel-coated stent graft implantation to induce neoin-
tima formation. Balloon injury was conducted with a 5F
occlusion balloon catheter via the left femoral artery. The
endothelial denudation was done by pulling the inflated
balloon catheter (120% of the diameter of the aorta) down
three times from the thoracic descending aorta to the site of
superior mesenteric artery (SMA).When neointima formed
at 4 weeks after balloon injury,22,23 three CG hydrogel-
coated stent grafts were implanted in the aorta of each
rabbit. The most upstream one incorporated with empty
pCAGGS acted as a negative control. The other two were
pCAGGS-LacZ-impregnated stent grafts. The 24 rabbits
were divided randomly into six groups (four in each group).
In groups 1, 2, and 3, the CG hydrogel-coated stent grafts
were plasmid-impregnated in the solution containing
10.0 mg/mL plasmid DNA. In groups 4, 5, and 6, the
pCAGGS-LacZ concentration in the loading solution of
plasmid-impregnation of stent grafts were 0.1 mg/mL, 1.0
mg/mL, and 10.0 mg/mL, respectively. The transgene
expression was evaluated at 1, 3, or 7 days after implanta-
tion in groups 1-3, and at 3 days in groups 4-6.
Stent graft implantation. Three CG hydrogel-coated
stent grafts (7 mm in diameter) were implanted at the
neointima formation portion of the aorta (6.0 0.3 mm in
diameter) due to balloon injury, as described previously20
(Fig 1, b). The diameter of the stent grafts was around 120%
of that of the aorta. A catheter sheath (6F  25 cm, Togo
Medikit Co, Ltd) was advanced via the right femoral artery
to the thoracic descending aorta under fluoroscopic guid-
ance with the Seldinger technique. The location of the
celiac trunk and SMA were identified, and the diameter of
the descending aorta was measured by aortography with a
straight pigtail measurement catheter (4F, Terumo). Hep-
arin (200 IU/kg) was administered through the catheterbefore the stent graft placement to prevent thrombosis.
The stent grafts were inserted into the sheath (6F 30 cm,
MEDIKIT Co, Ltd) and placed into the thoracic descend-
ing aorta with a pusher. The interval between the most
upstream stent graft and the second one was about 2 cm.
The most downstream one was placed just between the
celiac trunk and the SMA indicated by aortography.
Follow-up aortography was performed to confirm the loca-
tion and the patency of the stent grafts and the main
branches of the aorta. Animals received oral aspirin (2
mg/kg/day) to prevent thrombus formation until sacrifice.
Tissue retrieval and histologic analysis. The vessel
segment in which the most distal pCAGGS-LacZ-
impregnated stent graft was implanted, was snap-frozen in
liquid nitrogen and stored in 80°C for LacZ mRNA
analysis by real-time reverse transcriptase polymerase
chain reaction (RT-PCR). The vessel segments in which
the most upstream stent graft with pCAGGS and the
middle one with pCAGGS-LacZ were excised and cut
transversely into two parts. Half pieces of both vessel seg-
ments were fixed in 0.4% glutaraldehyde and 5 mM ethyl-
ene glycol tetraacetic acid (pH 7.4) in phosphate buffer
solution (PBS) for chemical staining of LacZ activity
(X-gal [5-bromo-4-chloro-3-indolyl--D-galactoside]
staining)24 or in 10% formaldehyde for conventional histol-
ogy. The other halves were embedded in Optimal Cutting
Temperature (OCT) compound for immunohistochemis-
try (see below). Vessel segments adjacent to both ends of
the pCAGGS-LacZ-loaded stent graft and several organ
tissues including the brain, heart, liver, and kidney were
retrieved to assess the extent of plasmid dissemination by
whole mount X-gal staining and RT-PCR.
For immunohistochemistry, cryosections (7 m thick-
ness) were incubated with primary antibodies diluted in
PBS supplemented with 10% goat serum for 90 minutes at
room temperature and then with corresponding secondary
biotinylated antibodies for 30 minutes, followed by incu-
bation with streptoavidin-conjugated peroxidase (Dako,
Carpinteria, Calif) for 30 minutes. The reaction was visual-
ized with DAB (Wako Pure Chemical Industries, Ltd,
Osaka, Japan) followed by counterstaining with hematox-
ylin (Muto Pure Chemicals Co, Ltd, Tokyo, Japan). Anti-
bodies used were: monoclonal mouse anti--smooth mus-
cle actin (-SMA) (1: 400; Sigma-Aldrich, St Louis, Mo),
monoclonal mouse anti-macrophage (RbM2) (1: 50;
TransGenic Inc, Kobe, Japan) andmonoclonal mouse anti-
endothelial cell (CD 31) (1: 50; Dako Cytomation,
Glostrup, Denmark).
RT-PCR analysis. The cDNAs were synthesized from
total RNA isolated with RNeasy kit (Qiagen Science, Ger-
mantown, Md) by using a high-capacity cDNA reverse
transcription kit (Applied Biosystems, Foster City, Calif).
The quantitative real-time PCR was performed using 7300
Real TimePCRSystem(AppliedBiosystems, FosterCity,Calif).
The sense primer, 5=-TCTGACTGACCGCGTTACTCC-3=,
was placed in the sequence just downstream of the tran-
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sequence in pCAGGS, and the antisense primer, 5=-
GTTTTCCCAGTCACGACGTT-3=, in the LacZ cDNA
sequence. The probe sequence was 5=-TGGCAAAGAAT-
TGATTTGCA-3=. The amplified PCR product was 149
bps. The 18S ribosomal RNA (18S-rRNA) (18S, ID# Hs
99999901_s1) was used as an internal control. Expression
of LacZ mRNA was normalized for 18S-rRNAmRNA and
results were expressed as fold change in mRNA com-
pared with the indicated controls. The sense and anti-
sense primers for semi-quantitative RT-PCR of LacZ
were 5=-TCTGACTGACCGCGTTACTCC-3= and 5=-
TCTTCGCTATTACGCCAGCTG-3=, respectively. Spe-
cific primers for -actin used as an internal control were as
follows: sense, 5=-AGAGTCCATCACGATGCCCGT-3=;
and antisense, 5=-ATGACGATATCGCCGCGCTCG-3=.
The amplified PCR products of LacZ and -actin were 217
and 471 bps, respectively.
Statistical analysis. All values are expressed as the
mean SE. The data were analyzed using one-way analysis
of variance (ANOVA) (Prism 5.0, GraphPad Software, Inc,
San Diego, Calif). If a statistically significant difference was
found, Newman-Keuls’ test was performed for post-hoc
analysis to detect the differences among groups. Values of
P  .05 were considered statistically significant.
RESULTS
Macroscopic and histologic findings of graft-
implanted sites. On gross examination, none of the stent
grafts had migrated. Gross luminal examination showed
that all stent grafts were patent without massive thrombus.
There was no space between the graft and aorta.
Hematoxylin and eosin (H&E)-stained sections re-
vealed neointima formation surrounding the stent graft and
ingrowth tissues into the graft in all rabbits with occasional
thrombus formation around the stent struts. The neoin-
tima between aorta and the graft was more cellular than
that in the infiltrated spaces between the fibers of the graft.
Another notable finding was the frequent presence of in-
flammatory cells including macrophages and foreign body
giant cells that phagocytized the graft fibers, which was also
found in the aorta with non-CG hydrogel-coated stent
graft and CG hydrogel-coated stent graft without impreg-
nation of plasmid in our preliminary experiments. The
EVG-stained sections showed that the medial layer of the
aortic wall lost its wavy disposition. The internal elastic
lamina remained intact. The extracellular matrix in the
neointima contained collagen and elastin fibers.
Stent graft mediated gene transduction into the
aortic wall. The expression of LacZ was detected in both
the aortic wall which had direct contact to the grafts and the
tissue ingrowth into the graft at the implantation sites of
pCAGGS-LacZ-loaded stent grafts in all animals, but not
of empty vector pCAGGS-loaded stent grafts, as evaluated
with X-gal staining (Fig 2, a-d). The X-gal staining-positive
blue colored areas were observed on the surface of the
aortic wall and especially in the tissue ingrowth into graft.
The positive signal was much denser where the neointimaformed intensely. The vessel segments adjacent to stent
grafts did not show any positive blue dots. Microscopic
examinations showed that X-gal positive cells were local-
ized mainly in the neointima and the tissues within the
grafts (Fig 3, a). Medial smooth muscle cells (SMCs) were
only occasionally X-gal-positive (data not shown), whereas
adventitial cells were never positive for X-gal staining. Im-
munohistochemical staining of serial cryosections of stent
grafted vessel segments showed that in the tissue ingrowth
into the graft as well as the neointima, both -SMA-
positive smooth muscle-like cells and RbM2-positive mac-
rophages were observed (Fig 3, b, c). These findings sug-
gested that LacZ-transfected cells were likely smooth
muscle cells and/or macrophages.
RT-PCR analysis detected LacZ mRNA in the aortic
segment at the implantation site of the pCAGGS-LacZ-
loaded stent grafts, but not its adjacent vessel segments
or at the implantation site of the pCAGGS-loaded stent
grafts (Fig 4), confirming that the LacZ mRNA expres-
sion was confined to the local vascular segments in
contact with pCAGGS-LacZ-loaded stent grafts. LacZ
mRNA was not detected in remote organs including the
brain, heart, liver, and kidney, indicating that stent graft
associated expression plasmid was not systemically dis-
seminated.
Gene transduction efficiency is dependent on time
and plasmid dose. The whole mount X-gal staining
showed that much more blue-colored positive dots were
observed on the aortic wall at day 1 compared with day 3
and day 7 (Fig 5, a). The intensity of the blue color in the
grafts was also stronger at day 1 than at days 3 and 7.
Quantitative real-time RT-PCR of LacZ mRNA expression
in the aortic wall confirmed a “burst” mRNA expression on
the first day (P .05 vs day 7), followed by gradual declines
at days 3 and 7 (Fig 5, b).
We next examined whether the level of transgene ex-
pression could be modulated by altering the plasmid-loading
amounts onto the CG hydrogel-coated stent graft. The
whole mount X-gal staining of the aortic segments showed
more blue positive dots at the loading concentration of
10.0 mg/mL compared with 1.0 and 0.1 mg/mL (Fig 6,
a). The grafts were also stained much more intensely at
10.0 mg/mL than at 1.0 and 0.1 mg/mL. Quantitative
RT-PCR of LacZ mRNA in the aortic wall revealed that
plasmid loading onto stent grafts at 10.0 mg/mL of plas-
mid gave a much higher level of the transgene expression
compared with those at 1.0 mg/mL (P  .01) and 0.1
mg/mL (P  .05) (Fig 6, b). These observations suggest
that CG hydrogel-coated stent graft mediated gene trans-
duction efficiency in the aortic wall is dependent on the
amount of plasmids.
DISCUSSION
Recently, considerable interest has focused on the
treatment of vascular diseases using local gene therapy.11-17
In addition to catheter-based infusions of vectors as the
method of gene delivery to vascular wall, device-based gene
delivery may be promising. Gene-eluting stents, which are
in th
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strategy, have been proven to be beneficial in gene delivery
to vascular wall in animal models.13-15 Stent graft-mediated
gene delivery is also expected to improve the therapeutic
effects of the device for atherosclerosis and aortic aneurysm.
To our knowledge, thus far only one report has shown the
usefulness of endograft as a delivery vehicle for intravascular
gene therapy.25 In that study, vascular SMCs were trans-
fected with an expression vector and then attached onto
stent grafts. The SMCs suffused in the stent graft expressed
a transgene product at the implanted site. This whole
procedure was relatively difficult and costly. In the present
study, controllable local gene transduction into aortic wall
Fig 2. Whole mount X-gal staining of vessel segments
revealed in both the aorta (a) and the neointima on the
indicated by black arrowheads. No blue dot was detectedof animal models was approached with genetically engi-neered stent grafts by electrostatically immobilizing the
plasmid DNA into biodegradable CG hydrogel coated on
the polyester fabric. The positively charged CG hydrogel
deposited on the surface of the stent graft can vigorously
absorb negatively charged plasmid DNA through polyion
complexation.18,19 Without CG hydrogel coating, absorp-
tion of plasmids onto the surface of stent graft is minimal,
and even if some amounts of plasmid are loaded, they
would be rapidly washed out by blood circulation. Plasmid
DNA loading can be accomplished by simply dipping the
CG hydrogel-coated stent grafts in plasmidDNA solutions.
Until the time of plasmidDNA loading to stent graft and its
use, prepared CG hydrogel-coated stent grafts can be
grafts. X-gal staining-positive blue dots and spots were
GS-LacZ-loaded graft (b). Parts of positive signals are
e control aorta (c) or the graft (d).and
pCAGstored in a sterile condition. Theoretically, we can manip-
n col
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and thereby gene expression by changing the hydrogel de-
gradability and the loaded amount of plasmids. Thus, CG
hydrogel-coated stent graft-based gene delivery is relatively
easier in the whole procedure and inexpensive and is poten-
tially controllable in the efficiency of gene transduction.
In the present study, we observed a burst expression of
Fig 3. X-gal staining and immunohistochemical staini
implanted vessel segment. a, X-gal staining followed by
(black arrows) in the neointima and the tissue ingrow
anti- smooth muscle actin antibody. The -smooth m
neointima, media, and vasa vasorum in the adventitia;
(RbM2) antibody. RbM2-positive macrophages (browLacZ in the aortic wall on the first day followed by a gradualdecline of the expression until day 7 (Fig 5). Our previous
studies18,19 showed that the temporal profiles of plasmid
release and gene expression reflect the CG hydrogel bio-
degradation profile, which could be altered by changing the
extent of cross-linking of CG hydrogel. The expression of
transgene-encoded protein is also dependent on the
amount of plasmid loaded onto CG hydrogel-coated stent
cryosections of the pCAGGS-LacZ-loaded stent graft
red nuclear counter staining showed blue positive dots
to the graft; b, Immunohistochemical staining using
actin-positive cells (brown color) were observed in the
munohistochemical staining using anti-macrophages
or) were observed mainly in the neointima.ng of
fast-
th in
uscle
c, Imgrafts. Plasmid loading can be controlled by changing
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of cationization of gelatin hydrogel. Hence, one could
control gene expression by changing the cross-linking con-
dition of CG hydrogel and loaded amounts of plasmids. It
is necessary to find an optimal CG hydrogel that shows high
transfection efficiency and an appropriate time profile of
plasmid DNA release and to optimize plasmid loading
conditions for each experimental purpose in future studies.
In addition, we could realize strictly localized gene delivery
as shown by the fact that no LacZ signal was detected in
vascular segments adjacent to the sites of stent graft implan-
tation or remote organs. Thus, the present method affords
a promising strategy for controllable gene delivery without
unwanted vector dissemination.
Morphologic analyses of clinical specimens of the an-
eurysm wall demonstrate some characteristic findings asso-
ciated with aortic aneurysms, including chronic infiltration
of inflammatory cells, degradation of extracellular matrix
(ECM), and apoptosis of SMCs.26,27 Besides, macrophages
express chemoattractant proteins and matrix metallopro-
teinases (MMPs) that are essential in the formation of
atherosclerotic plaques28 as commonly seen in aortic aneu-
rysm patients especially, at the aneurysm necks, where the
stent graft anchors. In our study, X-gal staining of cryosec-
Fig 4. Real-time reverse transcriptase polymerase chain reaction
(RT-PCR) analysis of aortic segments and various organs for LacZ
mRNA expression. LacZmRNA (a) and -actin mRNA as internal
control (b). LacZ mRNA was detected only in the pCAGGS-
LacZ-loaded, CG hydrogel-coated stent graft implanted vessel
segment. No dissemination was observed to distal or proximal
sections of the aorta or to remote organs. Positive control (PC) of
pCAGGS-LacZ transfected Cos 7 cells; 1: Vessel segment with
pCAGGS-LacZ-loaded stent graft; 2: Vessel segment with
pCAGGS-loaded stent graft; 3: Vessel segment proximal to stent
grafted (pCAGGS-LacZ) vessel segment; 4: Vessel segment distal
to stent grafted (pCAGGS-LacZ) vessel segment; 5: Brain; 6:
Heart; 7: Liver; and 8: Kidney.tion and the immunohistochemistry on serial sections sug-gested that transducted cells in the neointima and the tissue
ingrowth into the polyester graft were likely smooth muscle-
like cells and/or macrophages. However, we could not
unequivocally conclude that X-gal-positive cells were
smooth muscle-like cells or macrophages because double
staining of X-gal staining and immunohistochemistry using
anti--SMA and anti-RbM2 antibodies was not possible
due to technical difficulty including changes in the antige-
nicity during X-gal staining procedure. In addition, a lim-
ited number of medial SMCs were also gene-transfected.
These findings are significant because all these gene-
transfected cells are potential target cells to limit progres-
sion of aortic aneurysm and atherosclerosis and to acceler-
ate biologic fixation between stent grafts and aortic wall.
Although the graft material was incorporated with the
aorta, there was no evidence of endothelial cell-coverage of
the luminal surface in the sections analyzed by light micros-
copy. However, it could be possible that endothelial cells
might have been artificially removed during handling of the
incorporated stent grafts for analysis.
According to the previous studies on autopsy and ex-
planted stent grafts in humans,29,30 endovascular healing
leading to biologic fixation in humans is minimal compared
with experimental animals.10,31,32 In human vascular le-
sions, there is less neointimal formation and tissue ingrowth
into stent grafts. In our study, gene transduction was
observed mainly in the neointima and the tissue ingrowth
into stent grafts but limited in medial smooth muscle cells,
which leads to proliferation of smooth muscle cells and/or
other cell types and improves healing when an appropriate
therapeutic gene is selected.
In future clinical application, stent graft-mediated gene
delivery could be useful for the treatment of vascular dis-
eases including aortic aneurysm. In stent graft-based gene
therapy of aortic aneurysm, transduction into the vascular
wall and ingrowth tissues of genes that promote prolifera-
tion of SMCs and fibroblasts and production of ECM may
be favorable. For example, transductionof the genes encoding
peptide growth factors and cytokines such as platelet-derived
growth factors (PDGF), fibroblast-growth factor (FGF)
and transforming growth factor (TGF) could stimulate
proliferation of SMCs and fibroblasts and production of
ECM to promote incorporation of a stent graft with the
vascular wall.33 A gene that encodes tissue inhibitor of
metalloproteinase (TIMP) may promote accumulation of
ECM surrounding a stent graft.34 Transduction of genes
that encode intracellular signaling molecules to promote
cell proliferation, including Ras and c-Myc, might also be
useful in stimulating local cell proliferation.35-37 Because
the former group of genes encoding secreted and diffus-
ible proteins can affect neighboring nontransfected cells,
these therapeutic genes likely amplify the therapeutic ac-
tions. The relatively low level of transfection efficiency in
our study, as indicated by the spotty nature of the expres-
sion observed in Fig 2, suggests that effective clinical appli-
cation of this method will require the use of therapeutic
genes that encode secreted proteins but not intracellularly
acting proteins.
JOURNAL OF VASCULAR SURGERY
December 20091440 Zhong et alThere are several limitations in this study. First, to
facilitate delivery into rabbit aorta via femoral artery, the
polyester stent grafts were designed to be partially-covered
so that the stent graft profile could be decreased.20 Further-
more, the radial force of the handmade stent graft to the
aortic wall is not sufficiently equivalent due to the config-
uration of the Z-stent body. This may account for the
heterogeneous transduction of plasmid DNA to the aortic
tissue. In future studies, when using a therapeutic gene,
fully covered stent graft with a more proper stent configu-
ration should be used. Second, the optimal extents of
cross-linking and the cationization of the CG hydrogel
Fig 5. Time-dependent expression of LacZ in aortic seg
mount X-gal staining of vessel segments and stent grafts a
pCAGGS-LacZ at the plasmid concentration of 10.0 m
blocked areas in the upper panel. Much greater numbers
segment at day 1 after implantation compared with the
transcriptase polymerase chain reaction (RT-PCR) ana
transduction efficiency at day 1 was significantly highe
(ANOVA) and Newman-Keuls multiple comparison testcoated on graft were not scientifically well determined toprolong the time profile of its biodegradation to evaluate
the long-term effect of therapeutic gene transduction.
Third, to simulate the pathologic change of atherosclerotic
aorta possibly present at the portion of the aneurysmal
neck, we injured the aorta with a balloon catheter. In
nondamaged aorta, the transduction efficiency is very low.
Normal endothelial cells and smooth muscle cells are gen-
erally resistant to gene transduction, differently from neointi-
mal cells. However, this model is basically not the same as
atherosclerotic aorta. Further study is needed regarding these
points.
In conclusion, plasmid-loaded CG hydrogel-coated
s and stent grafts after graft stent implantation. a,Whole
1, 3, and 7 after implantation of stent grafts loaded with
L. Lower panel represents the magnified views of the
gal staining-positive blue dots are observed in the vessel
ents at days 3 and 7. b, Quantitative real-time reverse
f LacZ mRNA expression in the aortic segment. The
n at day 7 (*P  .05 by one-way analysis of variancement
t days
g/m
of X-
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lysis o
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).stent graft is a promising vehicle for local transgene delivery
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of therapeutic genes into vascular wall for inducing the
regression of aortic aneurysm or atherosclerosis and im-
proving graft function by facilitating the biologic healing
Fig 6. Dose-dependent expression of LacZ in aortic seg
mount X-gal staining of vessel segments and stent gra
pCAGGS-LacZ at the plasmid concentrations of either 0.
views of the blocked areas in the upper panel. Larger nu
vessel segment with stent grafts loaded with 10.0mg/mL
solutions. b, Quantitative real-time reverse transcripta
mRNA expression in the aortic segment. The transductio
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concentration by one-way analysis of variance (ANOVAbetween the aorta and graft.AUTHOR CONTRIBUTIONS
Conception and design: HZ, OM, KX, Y Takuwa
Analysis and interpretation: HZ, OM, KX, JS, YO, Y Tabata,
s and stent grafts after graft stent implantation. a,Whole
t day 1 after implantation of graft stents loaded with
, or 10.0mg/mL. Lower panel represents themagnified
of X-gal staining-positive blue dots are observed in the
id solution compared with 1.0 and 0.1mg/mL plasmid
lymerase change reaction (RT-PCR) analysis of LacZ
ciency in 10.0 mg/mL plasmid was significantly higher
ding concentration and f P .01 vs 1.0 mg/mL loading
Newman-Keuls multiple comparison test).ment
fts a
1, 1.0
mbers
plasm
se po
n effi
L loaY Takuwa
JOURNAL OF VASCULAR SURGERY
December 20091442 Zhong et alData collection: HZ, TO, YO
Writing the article: HZ
Critical revision of the article: HZ, OM, KX, TO, JS, YO,
Y Tabata, Y Takuwa
Final approval of the article: HZ, OM, KX, TO, JS, YO,
Y Tabata, Y Takuwa
Statistical analysis: HZ, YT
Obtained funding: OM
Overall responsibility: HZ, OM
REFERENCES
1. Greenberg RK, Chuter TA, Sternbergh WC 3rd, Fearnot NE, Zenith
Investigators. Zenith AAA endovascular graft: intermediate-term results
of the US multicenter trial. J Vasc Surg 2004;39:1209-18.
2. Greenhalgh RM, Brown LC, Kwong GP, Powell JT, Thompson SG,
EVAR trial participants. Comparison of endovascular aneurysm repair
with open repair in patients with abdominal aortic aneurysm (EVAR
trial 1), 30-day operative mortality results: randomised controlled trial.
Lancet 2004;364:843-8.
3. EVAR Trial Participants. Endovascular aneurysm repair and outcome in
patients unfit for open repair of abdominal aortic aneurysm (EVAR trial
2): randomised controlled trial. Lancet 2005;365:2187-92.
4. Brewster DC, Jones JE, Chung TK, Lamuraglia GM, Kwolek CJ,
Watkins MT, et al. Long-term outcomes after endovascular abdominal
aortic aneurysm repair: the first decade. Ann Surg 2006;244:426-38.
5. van Herwaarden ZA, van de Pavoordt ED, Waasdorp EJ, Albert Vos J,
Overtoom TT, Kelder JC, et al. Long-term single-center results with
AneuRx endografts for endovascular abdominal aortic aneurysm repair.
J Endovasc Ther 2007;14:307-17.
6. Peterson BG, Matsumura JS, Brewster DC, Makaroun MS, Excluder
Bifurcated Endoprosthesis Investigators. Five-year report of a multi-
center controlled clinical trial of open versus endovascular treatment of
abdominal aortic aneurysms. J Vasc Surg 2007;45:885-90.
7. White RA, Donayre CE, Walot I, Kopchok GE, Wilson EP, deVirgilio
C. Regression of an abdominal aortic aneurysm after endograft exclu-
sion. J Vasc Surg 1997;26:133-7.
8. Rodway AD, Powell JT, Brown LC, Greenhalgh RM. Do abdominal
aortic aneurysm necks increase in size faster after endovascular than
open repair? Eur J Vasc Endovasc Surg 2008;35:685-93.
9. Matsumura JS, Chaikof EL. Continued expansion of aortic necks after
endovascular repair of abdominal aortic aneurysms. EVT Investigators.
EndoVascular Technologies, Inc. J Vasc Surg 1998;28:422-30; discus-
sion 430-1.
10. Kusanagi M, Matsui O, Sanada J, Ogi T, Takamatsu S, Zhong H, et al.
Hydrogel-mediated release of basic fibroblast growth factor from a
stent-graft accelerates biological fixation with the aortic wall in a porcine
model. J Endovasc Ther 2007;14:785-93.
11. Laitinen M, Hartikainen J, Hiltunen MO, Eränen J, Kiviniemi M,
Närvänen O, et al. Catheter-mediated vascular endothelial growth
factor gene transfer to human coronary arteries after angioplasty. Hum
Gene Ther 2000;11:263-70.
12. Hedman M, Hartikainen J, Syvänne M, Stjernvall J, Hedman A, Kivelä
A, et al. Safety and feasibility of catheter-based local intracoronary
vascular endothelial growth factor gene transfer in the prevention of
postangioplasty and in-stent restenosis and in the treatment of chronic
myocardial ischemia: phase II results of the Kuopio Angiogenesis Trial
(KAT). Circulation 2003;107:2677-83.
13. Fishbein I, Alferiev I, BakayM, Stachelek SJ, Sobolewski P, Lai M, et al.
Local delivery of gene vectors from bare-metal stents by use of a
biodegradable synthetic complex inhibits in-stent restenosis in rat ca-
rotid arteries. Circulation 2008;117:2096-103.
14. Sharif F, Hynes SO, McMahon J, Cooney R, Conroy S, Dockery P, et
al. Gene-eluting stents: comparison of adenoviral and adeno-associated
viral gene delivery to the blood vessel wall in vivo. Hum Gene Ther
2006;17:741-50.
15. Walter DH, Cejna M, Diaz-Sandoval L, Willis S, Kirkwood L, Stratford
PW, et al. Local gene transfer of phVEGF-2 plasmid by gene-elutingstents: an alternative strategy for inhibition of restenosis. Circulation
2004;110:36-45.
16. Gaffney MM, Hynes SO, Barry F, O’Brien T. Cardiovascular gene
therapy: current status and therapeutic potential. Br J Pharmacol 2007;
152:175-88.
17. Gruchala M, Roy H, Bhardwaj S, Ylä-Herttuala S. Gene therapy for
cardiovascular diseases. Curr Pharm Des 2004;10:407-23.
18. Fukunaka Y, Iwanaga K,Morimoto K, KakemiM, Tabata Y. Controlled
release of plasmid DNA from cationized gelatin hydrogels based on
hydrogel degradation. J Control Release 2002;80:333-43.
19. Kushibiki T, Tomoshige R, Fukunaka Y, Kakemi M, Tabata Y. In vivo
release and gene expression of plasmid DNA by hydrogels of gelatin
with different cationization extents. J Control Release 2003;90:207-16.
20. Zhong H, Matsui O, Xu K, Ogi T, Okuda M, Liu Y, et al. Partially
covered stent-graft implantation in rabbit aorta: a new model to inves-
tigate bioactive stent-grafts in small animals. J Endovasc Ther 2009;16:
154-60.
21. Ross R. Atherosclerosis--an inflammatory disease. N Engl J Med 1999;
340:115-26.
22. Asada Y, Hara S, Tsuneyoshi A, Hatakeyama K, Kisanuki A, Marutsuka
K, et al. Fibrin-rich and platelet-rich thrombus formation on neointima:
recombinant tissue factor pathway inhibitor prevents fibrin formation
and neointimal development following repeated balloon injury of rabbit
aorta. Thromb Haemost 1998;80:506-11.
23. Han Y, Guo L, Yan C, Guo P, Deng J, Mai X, et al. Adenovirus-
mediated intra-arterial delivery of cellular repressor of E1A-stimulated
genes inhibits neointima formation in rabbits after balloon injury. J Vasc
Surg 2008;48:201-9.
24. Tam PP, Parameswaran M, Kinder SJ, Weinberger RP. The allocation
of epiblast cells to the embryonic heart and other mesodermal lineages:
the role of ingression and tissue movement during gastrulation. Devel-
opment 1997;124:1631-42.
25. Eton D, Yu H, Wang Y, Raines J, Striker G, Livingstone A. Endograft
technology: a delivery vehicle for intravascular gene therapy. J Vasc Surg
2004;39:1066-73.
26. Wassef M, Baxter BT, Chisholm RL, Dalman RL, Fillinger MF, Hei-
necke J, et al. Pathogenesis of abdominal aortic aneurysms: a multidis-
ciplinary research program supported by the National Heart, Lung, and
Blood Institute. J Vasc Surg 2001;34:730-8.
27. Henderson EL, Geng YJ, Sukhova GK, Whittemore AD, Knox J, Libby
P. Death of smooth muscle cells and expression of mediators of apo-
ptosis by T lymphocytes in human abdominal aortic aneurysms. Circu-
lation 1999;99:96-104.
28. Guo DC, Papke CL, He R, Milewicz DM. Pathogenesis of thoracic and
abdominal aortic aneurysms. Ann N Y Acad Sci 2006;1085:339-52.
29. Major A, Guidoin R, Soulez G, Gaboury LA, Cloutier G, Sapoval M, et
al. Implant degradation and poor healing after endovascular repair of
abdominal aortic aneurysm: an analysis of explanted stent-grafts. J
Endovasc Ther 2006;13:457-67.
30. McArthur C, Teodorescu V, Eisen L, Morrissey N, Faries P, Hollier L,
Marin ML. Histopathologic analysis of endovascular stent grafts from
patients with aortic aneurysm: does healing occur? J Vasc Surg 2001;
33:733-8.
31. Bashar AH, Kazui T, Terada H, Suzuki K, Washiyama N, Yamashita K,
Baba S. Histological changes in canine aorta 1 year after stent-graft
implantation: implications for the long-term stability of device anchor-
ing zones. J Endovasc Ther 2002;9:320-32.
32. Dal Ponte DB, Berman SS, Patula V, Kleinert L, Williams SK. Abdom-
inal aortic healing associated with a thin-walled Dacron-covered endo-
vascular graft in a canine model. J Endovasc Ther 2002;9:333-43.
33. Deguchi J, Namba T, Hamada H, Nakaoka T, Abe J, Sato O, et al.
Targeting endogenous platelet-derived growth factor B-chain by
adenovirus-mediated gene transfer potently inhibits in vivo smooth
muscle proliferation after arterial injury. Gene Ther 1999;6:956-65.
34. Akahane T, Akahane M, Shah A, Thorgeirsson UP. TIMP-1 stimulates
proliferation of human aortic smooth muscle cells and Ras effector
pathways. Biochem Biophys Res Commun 2004;324:440-5.
35. de Nigris F, Sica V, Herrmann J, Condorelli G, Chade AR, Tajana G, et
al. c-Myc oncoprotein: cell cycle-related events and new therapeutic
JOURNAL OF VASCULAR SURGERY
Volume 50, Number 6 Zhong et al 1443challenges in cancer and cardiovascular diseases. Cell Cycle 2003;2:
325-8.
36. Shi Y, Fard A, Galeo A, Hutchinson HG, Vermani P, Dodge GR, et al.
Transcatheter delivery of c-Myc antisense oligomers reduces neointimal
formation in a porcine model of coronary artery balloon injury. Circu-
lation 1994;90:944-51.37. Muto A, Fitzgerald TN, Pimiento JM, Maloney SP, Teso D, Paszkowiak
JJ, et al. Smooth muscle cell signal transduction: implications of vascular
biology for vascular surgeons. J Vasc Surg 2007;45 Suppl A:A15-24.Submitted May 1, 2009; accepted Jul 13, 2009.
